Odile Schiltz

Title: Odile Schiltz: Innovator in Cancer Research

Introduction

Odile Schiltz is a notable inventor based in Toulouse, France. She has made significant contributions to the field of cancer research, particularly in understanding the sensitivity to PI3K inhibitors. Her work has implications for the treatment of various human cancers, where the PI3K signaling pathway plays a crucial role.

Latest Patents

Odile Schiltz holds a patent for a "Marker for predicting the sensitivity to PI3K inhibitors." This invention addresses the challenge of predicting how tumors respond to PI3K-targeting drugs. The patent identifies a phosphopeptide characterized by the amino acid sequence PGPSDHQSQEASQFER, with a phosphorylated threonine residue at position 3. This discovery provides valuable insights into managing the heterogeneity of PI3K expression patterns in tumor samples.

Career Highlights

Throughout her career, Odile Schiltz has worked with prestigious institutions such as the Centre National de la Recherche Scientifique and the National Institute of Health and Medical Research. Her research has focused on the complexities of cancer biology and the development of targeted therapies.

Collaborations

Odile has collaborated with esteemed colleagues, including Emmanuelle Mouton-Barbosa and Marie-Pierre Bousquet. These partnerships have enhanced her research and contributed to the advancement of knowledge in the field.

Conclusion

Odile Schiltz's innovative work in cancer research exemplifies the importance of understanding molecular mechanisms in developing effective treatments. Her contributions continue to influence the landscape of cancer therapy and patient care.